Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

MRKMerck Sharp & Dohme LLCSigning up patients

A Clinical Study of V503 in Chinese Females Who Have Previously Received a Bivalent Human Papillomavirus (HPV) Vaccine (V503-108)

Papillomavirus Infections

2Calmworry score, out of 100

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

  • 5 insiders sold shares within a month

    Since Aug 13, 2026 · was worth 5, fading over time

    +1.9
Worry score2

Score over time

Stage
Phase 3
Patients
930 (planned)
Started
Oct 10, 2026
Main results expected
Dec 18, 2027
Fully finished
Dec 22, 2028
Results posted
not yet

What counts as success

The trial's main goal(s), called the “primary outcome.”

  • Percentage of Participants Who Are Seropositive by Competitive Luminex Immunoassay (cLIA) to HPV Types 6, 11, 31, 33, 45, 52, and 58 (Month 7)

    Measured over: Up to approximately 1 month post vaccination 3 (Up to approximately Month 7)

  • Percentage of Participants Who Experience at Least 1 Solicited Injection-site Adverse Event (AE)

    Measured over: Up to approximately Day 8 post any vaccination

  • Percentage of Participants Who Experience at Least 1 Solicited Systemic AE

    Measured over: Up to approximately Day 8 post any vaccination

  • Percentage of Participants Who Experience at Least 1 Serious AE (SAE)

    Measured over: Up to approximately Month 12

Changes Tremor has spotted

No changes since Tremor started watching this trial.
Show details (technical version)

Score inputs

  • insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)

Raw record changes

  • none yet

Trial ID NCT07785843 · record last updated 2026-10-22 · checked 2026-11-09 15:47 UTC

See the official record on ClinicalTrials.gov (NCT07785843) ↗